During the past decade, Gemeinschaftspraxis für Hämatologie und Onkologie conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 7 clinical trials were completed, i.e. on average, 29.2% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 7 clinical trials were completed. i.e. 63.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Gemeinschaftspraxis für Hämatologie und Onkologie" #1 sponsor was "Hoffmann-La Roche" with 10 trials, followed by "German CLL Study Group" with 4 trials sponsored, "Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest" with 4 trials sponsored, "Celgene" with 3 trials sponsored and "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 3 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Gemeinschaftspraxis für Hämatologie und Onkologie" #1 collaborator was "Roche Pharma AG" with 4 trials as a collaborator, "X-act Cologne Clinical Research GmbH" with 2 trials as a collaborator, "Zentrum für Klinische Studien Ulm" with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Bayer" with 1 trials as a collaborator. Other collaborators include 12 different institutions and companies that were collaborators in the rest 22 trials.

According to Clinical.Site data, the most researched conditions in "Gemeinschaftspraxis für Hämatologie und Onkologie" are "Chronic Lymphocytic Leukemia" (5 trials), "Lymphoma" (4 trials), "Breast Cancer" (2 trials), "Cholangiocarcinoma" (2 trials) and "Gallbladder Cancer" (2 trials). Many other conditions were trialed in "Gemeinschaftspraxis für Hämatologie und Onkologie" in a lesser frequency.

Most popular intervention types in "Gemeinschaftspraxis für Hämatologie und Onkologie" are "Drug" (29 trials), "Biological" (6 trials), "Radiation" (3 trials), "Other" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Lenalidomide" (5 trials), "Obinutuzumab" (5 trials), "Rituximab" (5 trials), "Atezolizumab" (4 trials) and "Placebo" (3 trials). Other intervention names were less common.

The vast majority of trials in "Gemeinschaftspraxis für Hämatologie und Onkologie" are 34 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Gemeinschaftspraxis für Hämatologie und Onkologie". undefined are not yet recruiting, 8 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Gemeinschaftspraxis für Hämatologie und Onkologie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Gemeinschaftspraxis für Hämatologie und Onkologie, 1 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".